CompletedNot Applicable

Iron and COVID-19 Vaccine Response

Kenya121 participantsStarted 2021-05-29

Plain-language summary

Vaccines often underperform in Africa compared to high-income countries. Why vaccines do not work as well in Africa remains uncertain. Malnutrition likely plays a role. Our study objective is to assess whether iron deficiency anaemia in young women impairs their immune response to the COVID-19 vaccine, and whether iron treatment improves their response.

Who can participate

Age range18 Years – 55 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: 18-55 years old Zinc protoporphyrin \> or equal 40 mmol/mol heme hemoglobin \< or equal 109 g/L no malaria no known HIV infection no medical condition that precludes study involvement no iron supplementation 1 week prior to study start no recent tuberculosis infection no vaccination of yellow fever or influenza prior to enrolment not pregnant Exclusion Criteria: \-

What they're measuring

Antibody titers

Timeframe: day 35

Antibody titers

Timeframe: day 63

Seroconversion

Timeframe: day 35

Seroconversion

Timeframe: day 63

Antibody avidity index

Timeframe: day 35

Antibody avidity index

Timeframe: day 63

Trial details

NCT IDNCT04915820

SponsorJomo Kenyatta University of Agriculture and Technology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-09-09

View on ClinicalTrials.gov More Iron Deficiency Anemia trials